Who are Certara's investors?

Certara's investors include Iaso Ventures.

How much funding has Certara raised?

Certara has disclosed $14.3M raised across 2 of its 4 known rounds.

Where is Certara headquartered?

Certara is headquartered in Radnor, US.

Certara

NASDAQ: CERT

Radnor, US · Founded 2017 · Delaware corporation · 1,490 employees on LinkedIn · 1 known investors

Certara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases. It serves pharmaceutical and biotech organizations seeking to make data-driven decisions and streamline regulatory submissions.

AI & Machine Learning Biotech Healthtech SaaS

Founders & leadership

John Gallagher IIISVP and Chief Financial Officer

Adrian McKemeyPresident, Certara Drug Development Solutions

Rona AnhaltChief Human Resources Officer

Daniel CorcoranSVP and General Counsel

Robert AspburyPresident, Certara Predicitive Technologies

Leif PedersenPresident, Chief Commercial Officer

William FeeheryCEO and Director

Jieun W. ChoeChief Strategy & Marketing Officer

Richard M. TraynorSenior Vice President and General Counsel

Craig R. RaynerPresident, Integrated Drug Development

Justin EdgePresident, Regulatory and Access

Nicolette D. ShermanChief Human Resources Officer

Investors · 1

Iaso VenturesreportedCambridgevia John Reynders · board

Reported raises · per SEC filings

Form D private placements

$14.3M disclosed across 2 of 4 rounds · 2021–2026

▶$8.6MraisedApr 2026 · 6 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Rona AnhaltExecutive Officer
Cynthia CollinsDirector
Eran BroshyDirector
Matthew WalshDirector
Stephen McLeanDirector
James CashmanDirector
David SpaightDirector
John Gallagher IIIExecutive Officer
Nancy KilleferDirector
Daniel CorcoranExecutive Officer
Arjun BediDirector
Rosemary CraneDirector
Robert AspburyExecutive Officer
John ReyndersDirector
Leif PedersenExecutive Officer
Adrian McKemeyExecutive Officer
Jon ResnickExecutive Officer, Director

Amount sold: $8.6M
First sale: Apr 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.7MraisedMar 2025 · 6 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

John Gallagher IIIExecutive Officer
Adrian McKemeyExecutive Officer
Rona AnhaltExecutive Officer
Cynthia CollinsDirector
Daniel CorcoranExecutive Officer
John ReyndersDirector
Stephen McLeanDirector
Matthew WalshDirector
Robert AspburyExecutive Officer
Eran BroshyDirector
Leif PedersenExecutive Officer
William FeeheryExecutive Officer, Director
David SpaightDirector
Rosemary CraneDirector
James CashmanDirector
Nancy KilleferDirector

Amount sold: $5.7M
First sale: Mar 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶Undisclosed amountofferedMar 2024 · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Cynthia CollinsDirector
Patrick SmithExecutive Officer
Rosemary CraneDirector
Nancy KilleferDirector
Nicolette ShermanExecutive Officer
Eran BroshyDirector
Matthew WalshDirector
Stephen McLeanDirector
John Gallagher IIIExecutive Officer
Robert AspburyExecutive Officer
David SpaightDirector
William FeeheryExecutive Officer, Director
Leif PedersenExecutive Officer
James Cashman IIIDirector
Richard TraynorExecutive Officer

Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶Undisclosed amountofferedSep 2021 · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jieun W. ChoeExecutive Officer
Richard M. TraynorExecutive Officer
Craig R. RaynerExecutive Officer
Nancy KilleferDirector
Carol G. GallagherDirector
Eric C. LiuDirector
Robert AspburyExecutive Officer
Justin EdgeExecutive Officer
Leif E. PedersenExecutive Officer
Ethan WaxmanDirector
Nicolette D. ShermanExecutive Officer
Cynthia CollinsDirector
Michael Andrew SchemickExecutive Officer
Sherilyn S. McCoyExecutive Officer
Mason P. SlaineDirector
Matthew WalshDirector
James E. Cashman IIIDirector
Stephen M. McLeanDirector
William F. FeeheryExecutive Officer, Director

Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

How Investors Are Reacting To Certara (CERT) Expanding Buybacks Amid Wider Losses And Leadership Changes - Simply Wall St Newssimplywall.st · Aug 2026

The Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Whyfinance.yahoo.com · Aug 2026

Certara Q2 2026 slides: revenue miss drives 16% stock decline By Investing.cominvesting.com · Aug 2026

Certara, Inc. (CERT) Stock Analysis: A Healthcare Investment With Limited Upside Potentialdirectorstalkinterviews.com · Jul 2026

Frequently asked questions

What does Certara do?: Certara provides biosimulation software, modeling, and regulatory services that support drug discovery and development across discovery, preclinical, clinical, regulatory, and market access phases. It serves pharmaceutical and biotech organizations seeking to make data-driven decisions and streamline regulatory submissions.
Who are Certara's investors?: Certara's investors include Iaso Ventures.
How much funding has Certara raised?: Certara has disclosed $14.3M raised across 2 of its 4 known rounds.
Where is Certara headquartered?: Certara is headquartered in Radnor, US.